Insider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells 2,007 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 2,007 shares of Nurix Therapeutics stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $12.04, for a total value of $24,164.28. Following the transaction, the insider now owns 39,601 shares in the company, valued at approximately $476,796.04. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Nurix Therapeutics Price Performance

Shares of NRIX stock traded down $0.45 on Tuesday, hitting $12.02. 1,505,032 shares of the company’s stock were exchanged, compared to its average volume of 943,265. The stock has a market cap of $590.80 million, a P/E ratio of -4.61 and a beta of 2.06. Nurix Therapeutics, Inc. has a 12 month low of $4.22 and a 12 month high of $18.12. The company has a 50 day moving average of $13.66 and a 200 day moving average of $9.79.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Thursday, February 15th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.26). The firm had revenue of $15.16 million during the quarter, compared to the consensus estimate of $30.66 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. Sell-side analysts predict that Nurix Therapeutics, Inc. will post -3.15 EPS for the current fiscal year.

Analyst Ratings Changes

NRIX has been the topic of several research reports. Royal Bank of Canada boosted their target price on Nurix Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a research note on Thursday, April 11th. Robert W. Baird boosted their price target on Nurix Therapeutics from $24.00 to $25.00 and gave the stock an “outperform” rating in a research report on Thursday, April 11th. Morgan Stanley boosted their price target on Nurix Therapeutics from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research report on Monday, February 26th. HC Wainwright lowered their price target on Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, February 20th. Finally, Wells Fargo & Company decreased their target price on Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Friday, February 16th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.33.

Institutional Investors Weigh In On Nurix Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. grew its stake in Nurix Therapeutics by 351.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock worth $58,000 after purchasing an additional 4,367 shares during the period. Quest Partners LLC bought a new position in Nurix Therapeutics in the fourth quarter worth approximately $59,000. Principal Financial Group Inc. boosted its holdings in Nurix Therapeutics by 14.8% in the third quarter. Principal Financial Group Inc. now owns 15,531 shares of the company’s stock worth $122,000 after acquiring an additional 2,002 shares in the last quarter. Jump Financial LLC bought a new position in Nurix Therapeutics in the fourth quarter worth approximately $158,000. Finally, SG Americas Securities LLC bought a new position in Nurix Therapeutics in the third quarter worth approximately $162,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.